|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Role of immunosuppression and tumor differentiation in predicting recurrence after liver transplantation for hepatocellular carcinoma: A multicenter study of 412 patients显示文摘AIM: To assess pre-orthotopic liver transplantation (OLT) factors that could be evaluated pre-operatively or con- trolled post-operatively associated with hepatocellular carcinoma (HCC) recurrence and disease-free survival after liver transplantation (LT).METHODS: Four hundred and twelve patients trans- planted for HCC between 1988 and 1998 in 14 French centers, who survived the postoperative period were studied. Kaplan Meier estimates were calculated for 24 variables potentially associated with recurrence of HCC. Uni- and multivariate analyses were conducted to iden- tify independent predictors of recurrence. RESULTS: Overall 5-year disease-free survival was 57.1%. By univariate analysis, variables associated with disease-free survival were: presence of cirrhosis (P = 0.001), etiology of liver disease (P = 0.03), α fetoprotein level (< 200, 200 to 2000, or > 2000; P < 0.0001), γ-GT activity (N, N to 2N or > 2N; P = 0.02), the number of nodules (1, 2-3 or ≥ 4; P = 0.02), maximal diameter of the largest nodule (< 3 cm, 3 to 5 cm or > 5 cm; P < 0.0001), the sum of the diameter of the nodules (< 3 cm, 3 to 5 cm, 5 to 10 cm or >10 cm; P < 0.0001), bi- lobar location (P = 0.01), preoperative portal thrombosis (P < 0.0001), peri-operative treatment of the tumor (P = 0.002) and chemoembolization (P = 0.03), tumor differentiation (P = 0.01), initial type of calcineurin inhibitor (P = 0.003), the use of antilymphocyte antibodies (P = 0.02), rejection episodes (P = 0.003) and period of LT (P < 0.0001). By multivariate analysis, 6 variables were independently associated with HCC recurrence: maximal diameter of the largest nodule (P < 0.0001), time of LT (P < 0.0001), tumor differentiation (P < 0.0001), use of anti-lymphocyte antibody (ATG) or anti-CD3 antibody (OKT3) (P = 0.005), preoperative portal thrombosis (P = 0.06) and the number of nodules (P = 0.06). CONCLUSION: This study identif ies immunosuppression, through the use of ATG or OKT3, as a predictive factor of tumor recurrence, and confi rms the prognostic value of tumor differentiation. | Thomas Decaens Franoise Roudot-Thoraval Solange Bresson-Hadni Carole Meyer Jean Gugenheim Francois Durand Pierre-Henri Bernard Olivier Boillot Philippe Compagnon Yvon Calmus Jean Hardwigsen Christian Ducerf Georges Philippe Pageaux Sébastien Dharancy Olivier Chazouillères Daniel Cherqui Christophe Duvoux | 2006 | World Journal of Gastroenterology2006，12，45： | 10 |
| 2 | Mycophenolate mofetil in combination with reduction of calcineurin inhibitors for chronic renal dysfunction after liver transplantation显示文摘 | Pageaux GP Rostaing L Calmus Y | 2006 | Liver Transpl2006，12，2： | 1 |
| 3 | Xenotrans plantation: physiopathology of hyperaeute and differentiated rejection, and therapeutic perspectives显示文摘 | MALASSAGNE B CALMUS Y HOUSSIN D | 2000 | Pathol Biol2000，48，4： | 1 |
| 4 | Hepatic expression of Class I and ClassⅡ major histocompatibility complex molecules in primary biliary cirrhosis:effect of ursodeoxycholic acid显示文摘 | Calmus Y Gane P Rouger P et a1 | 1990 | Hepatology1990，11，： | 1 |
| 5 | Liver transplantation using grafts with rare metabolic disorders显示文摘 | Astrid Schielke Filomena Conti Claire Goumard Fabiano Perdigao Yvon Calmus Olivier Scatton | 2014 | Digestive and Liver Disease2014，，： | 1 |
| 6 | Everolimus de novo in liver transplanta-tion显示文摘 | CALMUS Y DURRBACH A | 2009 | Gastroentcrol Clin Biol2009，334，： | 1 |
| 7 | Impaired expression of the peroxisome proliferator–activated receptor alpha during hepatitis C virus infection显示文摘 | Sébastien Dharancy Mathilde Malapel Gabriel Perlemuter Tania Roskams Yang Cheng Laurent Dubuquoy Philippe Podevin Filoména Conti Valérie Canva David Philippe Luc Gambiez Philippe Mathurin Jean-Claude Paris Kristina Schoonjans Yvon Calmus Stanislas Pol Joh | 2005 | Gastroenterology2005，，2： | 1 |
| 8 | Assessing Renal Function With Daclizumab Induction and Delayed Tacrolimus Introduction in Liver Transplant Recipients显示文摘 | Yvon Calmus Nassim Kamar Jean Gugenheim Christophe Duvoux Christian Ducerf Philippe Wolf Didier Samuel Claire Vanlemmens Martine Neau-Cransac Ephrem Salamé Olivier Chazouillères Nicole Declerck Georges-Philippe Pageaux Laurence Dubel Lionel Rostaing | 2010 | Transplantation2010，，12： | 1 |
| 9 | Effects of bile acid and cholestasis on major histocompatibility complex class I in human and rat hepatocytes显示文摘 | Hillaire S Boucher E Calmus Y | 1994 | Gastroenterology1994，107，3： | 1 |
| 10 | Differential effects of chenodeoxycholic and ursodeoxycholic acids on interleukin 1, interleukin 6and tumor necrosis factor- alpha production by monocytes显示文摘 | Calmus Y Guechot J Podevin P | 1992 | Hepatology1992，16，3： | 1 |
| 11 | Mycophenolate mofetil in combination with reduction of calcineurin inhibitors for chronic renal dysfunction after liver transplantation显示文摘 | Pageaux GP Rostaing L Calmus Y | 2006 | Liver Transpl2006，12，12： | 1 |
| 12 | NO-mediated vasodilation in the rat liver显示文摘 | Baimeng Zhang Didier Borderie Philippe Sogni Olivier Soubrane Didier Houssin Yvon Calmus | 1997 | Journal of Hepatology1997，，6： | 1 |
| 13 | Surgery versus medical follow-up in patients with asymptomatic primary hyperparathyroidism: a decision analysis 显示文摘 | Sejean K Calmus S Bonnichon P | 2005 | Ear J Endocrinol2005，153，： | 1 |
| 14 | Effects of bile acids and cholestasis on major histocompatibility complex class Ⅰ in human and rat hepatocytes显示文摘 | Hillaire S Boucher E Calmus Y | 1994 | Gastroenterology1994，107，3： | 1 |
| 15 | Spatial and temporal evolution of basalts and magnesian andesites ('bajaites') from Baja California, Mexico: The role of slab melts显示文摘 | CALMUS T AGUILLN-ROBLES A MAURY R C | 2003 | Lithos2003，66，： | 1 |
| 16 | Liver transplantation for hepatopulmonary syndrome: A ten-year experience in Paris, France显示文摘 | Camille Taille Jacquès Cadranel Agnes Bellocq Gabriel Thabut Olivier Soubrane Fran?ois Durand Philippe Icha? Christophe Duvoux Jacques Belghiti Yvon Calmus Hervé Mal | 2003 | Transplantation2003，，9： | 1 |
| 17 | Treatment of recurrent HCV infection following liver transplantation: results of a multicenter, randomized, versus placebo, trial of ribavirin alone as maintenance therapy atter one year of PeglFNo -2a plus ribavirin 显示文摘 | Calmus Y Duvoux C Pageaux G | 2012 | J Hepatol2012，57，3： | 1 |
| 18 | Predictive factors for survival and score application in liver retransplantation for hepatitis C recurrence显示文摘AIM: To identify risk factors associated with survival in patients retransplanted for hepatitis C virus(HCV) recurrence and to apply a survival score to this population.METHODS: We retrospectively identified 108 patients retransplanted for HCV recurrence in eight European liver transplantation centers(seven in France, one in Spain). Data collection comprised clinical and laboratory variables, including virological and antiviral treatment data. We then analyzed the factors associated with survival in this population. A recently published score that predicts survival in retransplantation in patients with hepatitis C was applied. Because there are currently no uniform recommendations regarding selection of the best candidates for retransplantation in this setting, we also described the clinical characteristics of 164 patients not retransplanted, with F3, F4, or fibrosing cholestatic hepatitis(FCH) post-first graft presenting with hepatic decompensation. RESULTS: Overall retransplantation patient survival rates were 55%, 47%, and 43% at 3, 5, and 10 years, respectively. Patients who were retransplanted for advanced cirrhosis had survival rates of 59%, 52%, and 49% at 3, 5, and 10 years, while those retransplanted for FCH had survival rates of 34%, 29%, and 11%, respectively. Under multivariate analysis, and adjusting for the center effect and the occurrence of FCH, factors associated with better survival after retransplantation were: negative HCV viremia before retransplantation, antiviral therapy after retransplantation, non-genotype 1, a Model for End-stage Liver Disease(MELD) score < 25 when replaced on the waiting list, and a retransplantation donor age < 60 years. Although the numbers were small, in the context of the new antivirals era, we showed that outcomes in patientswho underwent retransplantation with undetectable HCV viremia did not depend on donor age and MELD score. The Andrés score was applied to 102 patients for whom all score variables were available, producing a mean score of 43.4(SD = 6.6). Survival rates after the date of the first decompensation post-first liver transplantation(LT1) in the liver retransplantation(re LT) group(94 patients decompensated) at 3, 5, and 10 years were 62%, 59%, and 51%, respectively, among 78 retransplanted individuals with advanced cirrhosis, and 42%, 32%, and 16% among 16 retransplanted individuals with FCH. In the non-re LT group with hepatic decompensation, survival rates were 27%, 18%, and 9% at 3, 5, and 10 years, respectively(P < 0.0001). Compared with non-retransplanted patients, retransplanted patients were younger at LT1(mean age 48 ± 8 years compared to 53 ± 9 years in the no re LT group, P < 0.0001), less likely to have human immunodeficiency virus(HIV) co-infection(4% vs 14% among no re LT patients, P = 0.005), more likely to have received corticosteroid bolus therapy after LT1(25% in re LT vs 12% in the no re LT group, P = 0.01), and more likely to have presented with sustained virological response(SVR) after the first transplantation(20% in the re LT group vs 7% in the no re LT group, P = 0.028).CONCLUSION: Antiviral therapy before and after retransplantation had a substantial impact on survival in the context of retransplantation for HCV recurrence, and with the new direct-acting antivirals now available, outcomes should be even better in the future. | Alice Tung Wan Song Rodolphe Sobesky Carmen Vinaixa Jérome Dumortier Sylvie Radenne Francois Durand Yvon Calmus Géraldine Rousseau Marianne Latournerie Cyrille Feray Valérie Delvart Bruno Roche Stéphanie Haim-Boukobza Anne-Marie Roque-Afonso Denis Castaing Edson Abdala Luiz Augusto Carneiro D’Albuquerque Jean-Charles Duclos-Vallée Marina Berenguer Didier Samuel | 2016 | World Journal of Gastroenterology2016，22，18： | 1 |
| 19 | Treatment of recurrent HCV infection following liver transplantation: results of a multicenter, randomized, versus placebo, trial of ribavirin alone as maintenance therapy after one year of PegIFNct - 2a plus ribavirin 显示文摘 | Calmus Y Duvoux C Pageaux G | 2012 | J Hepatol2012，57，3： | 1 |
| 20 | Improving protein secondary structure prediction using a simple k-mer model 显示文摘 | Madera M Calmus R Thiltgen G | 2010 | Bioinformatics2010，26，5： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员